Kornimate/medical-research-clean huggingface dataset:
intrathecal morphine for radical robot assisted prostatectomy (tornado)

Conditions: Catheter Related Complication

Summary: investigators aim to compare the efficacy of intrathecal morphine, intravenous tramadol and transversus abdominis plane block in the treatment of catheter related bladder discomfort syndrome in patients scheduled for robotic assisted laparoscopic prostatectomy

patients scheduled for robot assisted laparoscopic prostatectomy will be treated depending on the belonging group. in the morphine group patients will receive intrathecal morphine 0,15 mg; in the transversus abdominis plane block patients will receive ropivacaine 80 mg; in the tramadol group patients will receive intravenous continuous infusion of tramadol 400 mg for the first 24 hours postoperatively. all data will be collected in the post anesthesia room and in the ward until the first post operative day.

Eligibility criteria:
inclusion criteria: * all patients scheduled for robotic assisted laparoscopic prostatectomy exclusion criteria: * coagulation disorders and platelet dysfunction for spinal arm * obesity for transversus abdominis plane block arm * left ventricular ejection fraction \< 30%, end-stage renal disease and neurological disorders for all groups
assessment of complications in patients who underwent lpn according to the cci

Conditions: Renal Cancer; Surgery-Complications

Summary: this study aims to compare the strength of the classical clavien-dindo classification system (cdc), which is a likert scale analysis versus the comprehensive complication index (cci), a new quantitative evaluation system, in patients undergoing laparoscopic partial nephrectomy (lpn).

prospectively collected data of sixty-two patients undergoing lpn with postoperative complications from november 2009 to august 2020 were evaluated retrospectively. postoperative complications were classified according to the cdcs and calculated using the cci calculator (https://www.assessurgery.com) quantitatively. major complications were determined as ≥ grade 3 complications according to the cdc. the complexity of the renal mass was defined according to the renal nephrometry score. the cut-off value for cci was analyzed by the roc analysis technique. the significance level was taken as p\<0.05.

Eligibility criteria:
inclusion criteria: * patients with complete data * patients with consent * patients \> 18 year-old * the surgeries performed by the surgeon eo exclusion criteria: * missing data * patients without consent * patients who underwent open or retroperitoneoscopic laparoscopic partial nephrectomy

Keywords: laparoscopy partial nephrectomy complication cci urology
spine mri in patients with deep brain stimulation (dbs)

Conditions: Parkinson Disease; Dystonia; Depression; Spinal Stenosis; Spinal Diseases

Summary: magnetic resonance imaging (mri) of patients implanted with deep brain stimulation (dbs) is under strict safety guidelines. depending on the body part being imaged, the safety may vary. many dbs patients will need a spine mri based on their clinical symptoms. however, the vendor safety guidelines are limiting in terms of possible mr pulse sequences. based on phantom safety data, we designed a set of mr pulse sequences deemed as safe as possible and the protocol allows acquisition of diagnostic quality mri images.

the patients who clinically require a spine mri will undergo a spine mri with our designed protocols to obtain diagnostic quality images. furthermore, a limited brain mri will be done before and after to ensure no peri-electrode tissue changes.

Eligibility criteria:
inclusion criteria * age between 18 and 85 years of age * participants must have undergone implantation of dbs electrodes. * participants must be able to understand the purpose of this research and must sign the informed consent form. * participants must understand that the role of this research is demonstrate the safety of spine mri in patients with dbs. exclusion criteria * participants who have serious cognitive or psychological impairments and cannot give informed consent. * participants who are unable to effectively or efficiently communicate, for example patients suffering from speech deficits (dysarthria, aphasia) or are non-english speaking.

Keywords: deep brain stimulation
thulium beam coagulation versus suture renorrhaphy for hemostasis of tumor bed in laparoscopic partial nephrectomy

Conditions: Renal Tumor; Renal Malignant Tumor

Summary: to compare the outcome of thulium beam coagulation versus suture renorrhaphy for hemostasis of the tumor bed in laparoscopic partial nephrectomy.

to date, no studies have compared the outcomes of thulium beam coagulation versus suture renorrhaphy for hemostasis of tumor bed in laparoscopic partial nephrectomy in patients with small renal messes (srms). this study aims to compare the outcome of thulium beam coagulation versus suture renorrhaphy for hemostasis of the tumor bed in laparoscopic partial nephrectomy. the investigators hypothesize that: conducted well designed, randomized prospective comparative study can help to identify which technique is better. using thulium beam coagulation for hemostasis of the tumor bed in laparoscopic partial nephrectomy can improve the outcome, shorten intraoperative ischemia time and decrease blood loss.

Eligibility criteria:
inclusion criteria: * ct1 single renal mass. exclusion criteria: 1. absolute contraindication for laparoscopic surgery (e.g., severe cardiopulmonary insufficiency, and chronic obstructive lung disease). 2. renal mass involving the hilum. 3. renal mass in patients with chronic kidney disease.

Keywords: thulium laser laparoscopic partial nephrectomy ischemia time small renal mass
a clinical study on the whole-course management (bcd-kpd-autohsct) scheme for patients with rimm

Conditions: Multiple Myeloma; Renal Injury

Summary: multiple myeloma (mm) is still an incurable hematological tumor, and renal involvement is the main factor of poor prognosis. the recovery of renal function can partially reverse its poor outcome. although the 5-year survival rate of mm patients has significantly improved after entering the era of new drugs, patients with severe renal insufficiency still have a high early mortality.the purpose of this study is to investigate whether early intensive chemotherapy can reverse the proportion of renal insufficiency, is to investigate the treatment effect of rimm patients with different renal pathological types, and is also to investigate whether autohsct can further partially save renal function in rimm patients.

for patients with multiple myeloma with renal impairment, the same disease stage and the same treatment regimen have different therapeutic effects. in the era of new drugs, studies have shown that early reduction of the free light chain in serum is the key to reversing renal function. the international myeloma working group recommends the following drugs for the treatment of rimm patients: 1. regimens based on proteasome inhibitors; 2. regimens based on immunomodulators. here, we explore a clinical study on the whole-course management (bcd-kpd-autohsct) scheme for patients with rimm.

Eligibility criteria:
inclusion criteria: 1. adults aged 18 years or older 2. confirmed diagnosis of symptomatic myeloma with renal impairment 3. confirmed myeloma-associated nephropathy (e.g. light chain cast nephropathy, al amyloidosis, midd etc.) on renal biopsy 4. willingness and eligibility for autologous hematopoietic stem cell transplantation exclusion criteria: 1. pre-existing chronic kidney disease unrelated to myeloma, such as diabetic nephropathy or hypertensive nephropathy 2. plasma cell leukemia or extramedullary plasmacytoma 3. contraindications or prior severe allergic reactions to study medications 4. co-existing malignancy 5. co-existing medical conditions unsuitable for enrollment as determined by researchers, such as recent cardiovascular event, active infection etc.
pilot study of physostigmine-enhanced opioid analgesia

Conditions: Postoperative Pain

Summary: the investigators hypothesize that the administration of physostigmine in the postoperative period after nephrectomy reduces opioid consumption.


Eligibility criteria:
inclusion criteria: * at least 18 years old * at least 50 kg * suitable for pca * asa 1-3 exclusion criteria: * bronchial asthma/severe or exacerbated copd * iritis * stenoses/spasms of intestine, urinary tract, biliary tract * closed traumatic brain injury * severely reduced left ventricular function (ef\<30%) * recent myocardial infarction * recent stroke * known allergy or hypersensitivity or contraindications against hydromorphone, physostigmine * history of alcohol or drug abuse * patients enrolled in another study * women of childbearing age without a negative pregnancy test
use of a support bra to reduce pain and improve surgical healing in women undergoing sternotomy for cardiac surgery

Conditions: Pain; Disruption or Dehiscence of Closure of Sternum or Sternotomy; Quality of Life

Summary: the primary purpose of this study is to examine whether a properly fitted support bra on females improves their quality of life post-sternotomy. specifically, does a support bra reduce discomfort, pain and wound dehiscence.

participants will be randomized to one arm of the study. one group will be fitted for a support bra and will be asked to wear this bra 24 hours a day for their 6 week post-course. they will submit to 3 questionnaires (at hospital discharge, at 3 weeks post-op and at their 6 week post-op visit with their surgeon. they will diary over this 6 week period re: pain, comfort, wound healing. the group in the no bra arm will also be measured for breast size and will submit to 3 questionnaires (at the same intervals) and will be asked to diary over their 6 week post-op course re: pain, comfort, wound healing. chronic pain and quality of life markers will be assessed through a 6month and 1 year follow-up telephone call and questionnaire.

Eligibility criteria:
inclusion criteria: * adult women (≥ 18 yrs) who are undergoing cardiac surgery with a sternotomy exclusion criteria: * patients who have had a previous mastectomy * previous radiotherapy to the chest * patients who do not read, write or have issues comprehending english * patients with cognitive impairments who will not be able to comply with the research study protocol * patients requiring physical restraints * patients requiring the application of a sternal binder

Keywords: pain comfort healing quality of life
a cohort of patients undergoing percutaneous coronary intervention

Conditions: Acute Coronary Syndrome; Percutaneous Coronary Intervention; Myocardial Infarction; Unstable Angina

Summary: to investigate the risk factors involved in the occurrence and prognosis of the patients with acute coronary syndrome, patients undergoing percutaneous coronary intervention will be recruited and followed up for at least 2 years.

patients with acute coronary syndrome undergoing percutaneous coronary intervention will be recruited and prospectively followed up for the incidence of major adverse cardiovascular events (mace events), including all-cause mortality, cardiovascular mortality, ischemic stroke. blood and fecal samples will be collected for further analysis. the basic and clinical information will be collected such as diagnosis, medical history, laboratory test results, therapy methods, prognosis and follow-up information. the risk factors involved in the occurrence and prognosis of acute coronary syndrome will be investigated.

Eligibility criteria:
inclusion criteria: * diagnosed as acute coronary syndrome and needed to undergo percutaneous coronary intervention. * \>18 years old. exclusion criteria: * with malignant tumors, acute infectious diseases and advanced liver diseases. * won't sign an inform consent.
association of probiotics with neurostimulation of dermatome t6: effect on weight loss in obese patients

Conditions: Weight Loss

Summary: patients will be randomized into 2 groups: * group 1:patients undergoing pens t6, who also received probiotics, during 10 weeks. * group 2: patients undergoing pens t6 during 10 weeks. they will not received probiotics weight loss after 10 weeks of treatmente will be assessed.

patients will be randomized into 2 groups: * group 1:patients undergoing percutaneous electrical stimulation of dermatome t6 (pens t6), who also received probiotics (adomelle 1 caps/12h), during 10 weeks. * group 2: patients undergoing pens t6 during 10 weeks. they will not received probiotics weight loss after 10 weeks of treatmente will be assessed.

Eligibility criteria:
inclusion criteria: * bmi \> 30 kg/m2 exclusion criteria: * patients with pacemakers or implanted electrical devices. * pregnant women * history of allergy to probiotics
simultaneous integrated boost vs. routine imrt in limited-stage small-cell lung cancer

Conditions: Small-cell Lung Cancer

Summary: thoracic radiotherapy concurrent with chemotherapy stands for the standard regime for limited staged small cell lung cancer. involved node radiation（inf） replaced elective node irradiation（eni） as the more popular since several trails compared the two regimes. simultaneous integrated boost imrt becomes mature with advancing in imrt and vmat. the investigator hypothesis that sib-imrt can confine the dose for organs at risk to reduce the toxicities compared with routine imrt in limited disease small-cell lung cancer.

all patients recruited divided into two arms：sib-imrt or routine imrt，in the routine arm，the prescription dose was 60gy/2gy/30f，and in the sib arm ，60gy was given to the field of the tumor and metastatic lymph nodes，50gy was given to cr lesion and high-risk prevention. the physical advantages of sib-imrt are to reduce the radiation dose of organs that are at risk in the lungs, esophagus, and heart ensuring the adequate dose for tumor area at the same time. the investigators are carrying out this trial to compare the efficacy, safety, side effects, and type of failure of the two radiotherapy techniques, which will provide a new choice and reliable basis for the future dose-segmentation study of limited-stage small-cell lung cancer.

Eligibility criteria:
inclusion criteria: * 18-70 years old,kps≥80 * pathological small cell lung cancer * staged as limited disease sclc（contralateral hilar invasion not included） * receive radiotherapy concurrent or sequential with chemotherapy，if induction chemotherapy，got pr or sd * no other tumors * no serious medical diseases and dysfunction of major organs * understand this study，able to complete the treatment，accept the following up and sign the informed consent * contraception in women of childbearing age. exclusion criteria: * other malignant tumor（historically or simultaneously）curable non-melanoma skin cancer and cervical carcinoma in situ not included * uncontrolled heart disease or myocardial infarction within 6 months * history of mental illness * pregnancy or lactation * uncontrolled diabetes、hypertension

Keywords: limited-stage small-cell lung cancer radiotherapy simultaneous integrated boost
use of ramipril and felodipine combination therapy in hypertension: an effectiveness study with local patients in argentina

Conditions: Hypertension

Summary: primary: * to assess effectiveness of ramipril-felodipine in hypertensive argentinean patients secondary: * to assess tolerability of ramipril-felodipine in hypertensive argentinean patients.


Eligibility criteria:
inclusion criteria: * outpatient * patients who couldn´t control their hypertension after 6 weeks of treatment with monotherapy (calcium blockers, beta blockers, diuretics, ace inhibitors, at2 blockers)(uncontrolled hypertension). exclusion criteria: * already on fixed-dose combination treatment for hypertension * contraindication to angiotensin converting enzyme (ace) inhibitors or ccb therapy * known hypersensitivity to felodipine (or other dihydropyridines), ramipril, other ace or any of the excipients of ramipril felodipine. * history of angioedema * unstable haemodynamic conditions: cardiovascular shock, untreated heart failure, acute myocardial infarction, unstable angina pectoris, stroke. * patients with av block ii or iii * severely impaired hepatic function. * pre-existing bilateral renal artery stenosis or stenosis of the artery to a solitary kidney * pregnant and lactating mothers * patients on dialysis or haemofiltration. * patients with creatinine clearance \< 20ml/min * use of potassium sparing diuretics * severe hypertension (sbp ≥ 180 mmhg or dbp ≥ 110 mmhg) the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
evaluating the safety and efficacy of sb injection in patients with advanced or primary hepatocellular carcinoma (hcc)

Conditions: Hepatocellular Carcinoma

Summary: the purpose of this study is to determine efficacy of sb injection in hepatocellular carcinoma (hcc).

all eligible patients will receive sb injection therapy for 6 cycles (14\~21 days for each cycle). efficacy wll be evaluated every 3 cycles.

Eligibility criteria:
inclusion criteria: 1. age of 18 years or over 2. patients with hepatocellular carcinoma progression (hcc) and primary liver cancer as a diagnostic imaging test (eg, x-ray, ct, scan, ultrasound) can be measured in patients with a lesion 3. directly to standard therapy (surgery, rf ablation, tace) is not possible, patients with advanced liver cancer. however, the standard treatment of the subject or subjects entirely voluntary participation of subjects participating at the discretion of the doctor or researcher can be deemed included in the selected target. 4. life expectancy ≥ 5 months 5. ecog status 0, 1, 2 patients 6. child-pugh classification a, b patients 7. plt 70,000, anc 1,000 or more patients (ot / pt \<upper normal limit x 5.0, bilirubin \<upper normal limit x 3.0) 8. female volunteers admitted to the study must be using a reliable means of contraception and must have a negative blood or urine pregnancy test at least 7 days ago 9. patients or their legal representatives who have signed the informed consent form exclusion criteria: 1. last 4 weeks the patients who had participated in another clinical trial 2. last 4 weeks the patients who received chemotherapy 3. associated with hepatocellular carcinoma in patients with a history of malignant tumor 4. hepatectomy or liver transplantation patients who received treatment. 5. active systemic infection requiring medical treatment 6. uncontrolled hypertension or diabetes mellitus. 7. clinically significant cardiac disease (myocardial infarction / angina / severe arrhythmia / congestive heart failure) 8. autoimmune diseases (systemic lupus erythematosus: sle / rheumatoid arthritis / myasthenia gravis) and the patients currently being treated 9. presence or history of malignancy other than hepatocellular carcinoma within 5 years 10. patients who have history of allergy with this investigational drug. 11. obvious cognitive or physical impairment that would prevent participation 12. pregnancy, lactation period and don't using contraception earnest patients

Keywords: sbp injection hcc
coagulation profile of patients undergoing crs(cytoreductive surgery) and hyperthermic intraperitoneal chemotherapy

Conditions: Haematological Abnormality

Summary: to study the changes in coagulation profile in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. the objective of the study is to determine the utility of thromboelastography in comparison to standard coagulation tests in assessing the coagulopathy in patients undergoing crs with hipec.

this is a prospective observational study conducted in 60 patients undergoing crs with hipec in rgcirc from march 2015- march2016 after taking permission from the institutional review board and informed written consent from the patients. arterial blood samples were collected before and after hipec and on first and second postoperative day for pt,aptt inr,teg and abg. statistical analysis was done using chi square test and unpaired t- test for categorical and continuous variables. pearson's correlation coefficient was calculated for analysing the correlation between the variables .p - value \<0.05 was considered statistically significant.

Eligibility criteria:
inclusion criteria: * asa 1\&2 * undergoing crs with hipec exclusion criteria: * extremities of age * patients with coagulopathy * patients on anticoagulant preoperatively sever organ dysfunctions

Keywords: thromboelastography, chemotherapy,hyperthermic
individualization of ganciclovir and valganciclovir doses using bayesian prediction in renal transplant patients.

Conditions: Infection in Solid Organ Transplant Recipients

Summary: the objective of the present study is to optimize intravenous ganciclovir(gcv) and oral valganciclovir (vgcv)doses, advised by the drug exposure, indicated by the area under the concentration time curve (auc), in renal transplant patients receiving oral vgcv or intravenous gcv for cmv prophylaxis or treatment. the initial doses will be calculated according to population pharmacokinetic model. subsequent doses will be adjusted according to plasma gcv concentrations, using the bayesian approach. this method of dose adjustments could lead to increase the percentage of patients achieving a therapeutic exposure.

the area under the concentration time curve of serum concentrations of gcv is an indicator of systemic exposure to the drug and is related to the effectiveness and safety. according to the population model developed by our group, less than 16% of patients treated achieve the therapeutic goal of auc (40 to 50 mcg • h / l) after drug dosing according to summary of product characteristics (spc). especially, patients with impaired renal function values (creatinine clearance (crc)l \ 70 ml / min) would be overdosed and underdosed, respectively, with the risk of more adverse effects or therapeutic failure. therefore, the individualization of the dosage of gcv, can contribute greatly to achieve optimal exposure to the drug in transplant patients, especially in the cases of extreme values of renal function (crcl decreased and high). as a consequence, minimize adverse effects, ensure greater efficiency in the target population and reduce associated costs.

Eligibility criteria:
inclusion criteria: * subjects must be 18 or older, weigh more than 34kg and may be of either sex and race. * subjects must be willing to give informed consent (ic) in writing and be able to do and follow the study. if a subject cannot give informed consent in writing , a legal representative could sign in his place. * women of childbearing potential should perform a pregnancy test at the time of entry and accept the use of a medically acceptable contraceptive method during the study. exclusion criteria: * creatinine clearance (crcl )\<10 ml / min. * subjects may not have a history of type i hypersensitivity or idiosyncratic reactions to drugs ganciclovir/valganciclovir * pregnancy women. * women breast feeding * subjects may not present at time of inclusion any clinically significant disease that could interfere with study evaluations. * previous participation in another clinical trial sponsored by pharmaceutical industry, in which the promoter and the protocol set which should be the treatment for cmv.

Keywords: cytomegalovirus renal transplant